Truvalin 25; Truvalin 100; Truvalin 200; Truvalin 300 25 mg, 100 mg, 200 mg, 300 mg FC Tablet
PDF Leaflet Revision Date: 29 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of schizophrenia and manic episodes associated with bipolar disorder.
Dosage (summary)
Adults: Start with 50 mg on Day 1, titrate to 300-450 mg/day for schizophrenia; 100 mg on Day 1, titrate to 400-800 mg/day for bipolar mania.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; safety not demonstrated.
Key Drug Interactions
- CNS depressants
- QT prolonging agents
- CYP3A4 inhibitors
Contraindications
- Hypersensitivity
- Pregnancy and lactation
- Severe liver and renal impairment
Common side effects
- Somnolence
- Dizziness
- Dry mouth
- Weight gain
- Extrapyramidal symptoms
Counselling Points
- Monitor for suicidal thoughts
- Avoid alcohol
- Report signs of infection
- Gradual withdrawal recommended
Serious warnings
- Risk of suicidal thoughts
- Neutropenia and agranulocytosis
- Hyperglycaemia
- QT prolongation
- Severe cutaneous adverse reactions
Important Disclaimer
The Truvalin 25; Truvalin 100; Truvalin 200; Truvalin 300 25 mg, 100 mg, 200 mg, 300 mg FC Tablet professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
